Cost of Illness from the Public Payers' Perspective in Patients with Ankylosing Spondylitis in Rheumatological Care.
Strömbeck, Britta LU ; Englund, Martin LU
; Bremander, Ann
LU
; Jacobsson, Lennart
LU
; Kedza, Ljuba
; Kobelt, Gisela
LU
and Petersson, Ingemar
LU
(2010)
In Journal of Rheumatology
37.
p.2348-2355
- Abstract
- OBJECTIVE: To estimate the incremental costs to public payers for patients with ankylosing spondylitis (AS) of working age compared with reference subjects from the general population. METHODS: We investigated total costs for 3 years (2005-2007) in 116 outpatients under 66 years of age with AS attending rheumatological care in Malmö, Sweden. Mean (SD) age was 46 (11) years and mean (SD) disease duration was 24 (11) years. Two subjects perAS patient matched for age, sex, and residential area were selected from the Population Register to serve as a reference group. We retrieved data concerning sick leave, prescription drugs, and healthcare consumption from Swedish health-cost registers by the unique personal identification numbers. RESULTS:... (More)
- OBJECTIVE: To estimate the incremental costs to public payers for patients with ankylosing spondylitis (AS) of working age compared with reference subjects from the general population. METHODS: We investigated total costs for 3 years (2005-2007) in 116 outpatients under 66 years of age with AS attending rheumatological care in Malmö, Sweden. Mean (SD) age was 46 (11) years and mean (SD) disease duration was 24 (11) years. Two subjects perAS patient matched for age, sex, and residential area were selected from the Population Register to serve as a reference group. We retrieved data concerning sick leave, prescription drugs, and healthcare consumption from Swedish health-cost registers by the unique personal identification numbers. RESULTS: The mean total cost for the 3-year period 2005-2007 was US $37,095 (SD $30,091) for patients with AS, and $11,071 (SD $22,340) for the reference group. The mean indirect cost was $19,618 and $5905, respectively. Mean cost for healthcare was $8998 for the AS patients and $4187 for the reference subjects, and mean cost for drugs was $8479 and $979, respectively. The patients with AS treated with biological therapy constituted 80% of the total drug cost, but just 40% of the cost for disability pension. CONCLUSION: Patients with AS had 3-fold increase in costs compared to reference subjects from the general population, and the drug costs were almost 10 times as high. Production losses (indirect cost) represented more than half of total cost (53%). (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1665228
- author
- Strömbeck, Britta
LU
; Englund, Martin
LU
; Bremander, Ann
LU
; Jacobsson, Lennart
LU
; Kedza, Ljuba
; Kobelt, Gisela
LU
and Petersson, Ingemar
LU
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Rheumatology
- volume
- 37
- pages
- 2348 - 2355
- publisher
- Journal of Rheumatology Publishing Company Limited
- external identifiers
-
- wos:000284301900026
- pmid:20716657
- scopus:78149273147
- ISSN
- 0315-162X
- DOI
- 10.3899/jrheum.100099
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Physiotherapy (Closed 2012) (013042000), Department of Orthopaedics (Lund) (013028000), Internal Medicine Research Unit (013242520)
- id
- 9ef490dc-a82c-4b24-a1da-246ef950d73a (old id 1665228)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/20716657?dopt=Abstract
- date added to LUP
- 2016-04-04 08:52:40
- date last changed
- 2022-01-29 07:22:31
@article{9ef490dc-a82c-4b24-a1da-246ef950d73a,
abstract = {{OBJECTIVE: To estimate the incremental costs to public payers for patients with ankylosing spondylitis (AS) of working age compared with reference subjects from the general population. METHODS: We investigated total costs for 3 years (2005-2007) in 116 outpatients under 66 years of age with AS attending rheumatological care in Malmö, Sweden. Mean (SD) age was 46 (11) years and mean (SD) disease duration was 24 (11) years. Two subjects perAS patient matched for age, sex, and residential area were selected from the Population Register to serve as a reference group. We retrieved data concerning sick leave, prescription drugs, and healthcare consumption from Swedish health-cost registers by the unique personal identification numbers. RESULTS: The mean total cost for the 3-year period 2005-2007 was US $37,095 (SD $30,091) for patients with AS, and $11,071 (SD $22,340) for the reference group. The mean indirect cost was $19,618 and $5905, respectively. Mean cost for healthcare was $8998 for the AS patients and $4187 for the reference subjects, and mean cost for drugs was $8479 and $979, respectively. The patients with AS treated with biological therapy constituted 80% of the total drug cost, but just 40% of the cost for disability pension. CONCLUSION: Patients with AS had 3-fold increase in costs compared to reference subjects from the general population, and the drug costs were almost 10 times as high. Production losses (indirect cost) represented more than half of total cost (53%).}},
author = {{Strömbeck, Britta and Englund, Martin and Bremander, Ann and Jacobsson, Lennart and Kedza, Ljuba and Kobelt, Gisela and Petersson, Ingemar}},
issn = {{0315-162X}},
language = {{eng}},
pages = {{2348--2355}},
publisher = {{Journal of Rheumatology Publishing Company Limited}},
series = {{Journal of Rheumatology}},
title = {{Cost of Illness from the Public Payers' Perspective in Patients with Ankylosing Spondylitis in Rheumatological Care.}},
url = {{http://dx.doi.org/10.3899/jrheum.100099}},
doi = {{10.3899/jrheum.100099}},
volume = {{37}},
year = {{2010}},
}